Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

被引：0
|
作者：
Ratnayake, G. M. [1 ]
Koffas, A. [1 ]
Theocharopoulos, I [1 ]
Hayes, A. [1 ]
Navalkissoor, S. [1 ]
Gnanasegaran, G. [1 ]
Quigley, A. M. [1 ]
Khoo, B. [1 ]
Mandair, D. [1 ]
Grossman, A. [1 ]
Caplin, M. [1 ]
Alsadik, S. [1 ]
Clark, R. [1 ]
Toumpanakis, C. [1 ]
机构：
[1] Royal Free Hosp, ENETS Ctr Excellence, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
carcinoid syndrome; prrt;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H24
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome
    Maas, C.
    Mulders, M.
    Mirzaian, M.
    van den Berg, S.
    Brabander, T.
    de Herder, W. W.
    Hofland, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 207 - 207
  • [22] Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
    Unal, Caglar
    Selcuk, Nalan Alan
    Biricik, Fatih Selcuk
    Alan, Ozkan
    Ordu, Cetin
    Selvi, Oguzhan
    Sakin, Abdullah
    Sever, Nadiye
    Topcu, Zeynep Alaca
    Akyildiz, Arif
    Coban, Eyup
    Evrensel, Turkan
    Ozcan, Erkan
    Dursun, Bengu
    Yucel, Kadriye Bir
    Arak, Haci
    On, Sercan
    Guzel, Halil Goksel
    Salim, Derya Kivrak
    Kalkan, Ziya
    Oruc, Zeynep
    Duymaz, Tomris
    Seyyar, Mustafa
    Agdas, Gozde
    Ozcelik, Melike
    Paksoy, Nail
    Cetin, Bulent
    Yararbas, Kanay
    Saglam, Sezer
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2023, 7 (03): : 232 - 242
  • [23] Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1503 - 1508
  • [24] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [25] Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy
    Mora-Ramirez, Erick
    Santoro, Lore
    Cassol, Emmanuelle
    Ocampo-Ramos, Juan C.
    Clayton, Naomi
    Kayal, Gunjan
    Chouaf, Soufiane
    Trauchessec, Dorian
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Deshayes, Emmanuel
    Bardies, Manuel
    MEDICAL PHYSICS, 2020, 47 (09) : 4602 - 4615
  • [26] Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm
    Bober, Barbara
    Saracyn, Marek
    Lubas, Arkadiusz
    Kolodziej, Maciej
    Brodowska-Kania, Dorota
    Kapusta, Waldemar
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2022, 25 (01) : 54 - 61
  • [27] Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours
    Davidson, Jennifer
    Hull, Avril
    Mead, Trish
    Lunt, Brian
    Stewart, Allan
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2022, 53 (02) : S22 - S30
  • [28] How We Do It: A Multidisciplinary Approach to 177LU DOTATATE Peptide Receptor Radionuclide Therapy
    Burkett, Brian J.
    Dundar, Ayca
    Young, Jason R.
    Packard, Annie T.
    Johnson, Geoffrey B.
    Halfdanarson, Thorvardur R.
    Eiring, Rachel A.
    Gansen, Denise N.
    Patton, Cynthia M.
    Kendi, A. Tuba
    RADIOLOGY, 2021, 298 (02) : 261 - 274
  • [29] 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)
    van Bogaert, C.
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas-Guix, C.
    Critchi, G.
    Marin, C.
    Hendlisz, A.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 161 - 161
  • [30] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
12345